Last reviewed · How we verify

NCT02898896

Coronary Artery Disease (CAD) in Suppressed HIV-infected

Terminated NA Last updated 12 August 2019
What this trial tests

NA trial testing blood test in Virus-HIV in 62 participants. Terminated before completion.

Timeline
1 March 2017
Primary endpoint
5 January 2018
5 January 2018

Quick facts

Lead sponsorUniversity Hospital, Montpellier
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeprevention
Enrollment62
Start date1 March 2017
Primary completion5 January 2018
Estimated completion5 January 2018
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Montpellier

Who can join

Adults 48 to 100, any sex, with Virus-HIV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

HIV-infected patients with intermediate-high risk have a high prevalence of CAD and a substantial proportion of obstructive CAD. Degree of stenosis is associated with immunoactivation (lymphocyte and monocyte) and microbial translocation

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of blood test

Trials testing the same drug.

Other University Hospital, Montpellier trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02898896.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing